ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 59 filers reported holding ONCOMED PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $242,000 | -42.4% | 59,100 | -36.4% | 0.01% | -50.0% |
| Q3 2017 | $420,000 | +128.3% | 92,900 | +288.7% | 0.01% | +16.7% |
| Q4 2016 | $184,000 | -33.6% | 23,900 | -1.2% | 0.01% | -25.0% |
| Q3 2016 | $277,000 | -8.3% | 24,200 | -1.2% | 0.02% | -33.3% |
| Q2 2016 | $302,000 | +20.8% | 24,500 | -1.0% | 0.02% | +50.0% |
| Q1 2016 | $250,000 | -33.5% | 24,750 | +48.2% | 0.02% | -69.2% |
| Q4 2015 | $376,000 | – | 16,700 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |